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Background: At present, there are no widely accepted criteria for the use of radiofrequency ablation (RFA) for the
treatment of colorectal liver metastases (CLM) in the context of effective modern-agent therapies. We aimed to
define selection criteria for patients with liver-limited CLM who may benefit from adding RFA to systemic therapy
with respect to long-term disease control.
Methods: Between 2002 and 2007, 88 consecutive patients received RFA for liver-only CLM during partial remission
(PR), stable disease (SD), or progressive disease (PD) after systemic therapy. At a median follow-up of 8.2 years
(range 5.2-11.1 years), clinical data were correlated to overall survival (OS) and recurrence-free survival (RFS).
Results: Poor OS and RFS correlated significantly with PD to systemic therapy before RFA (HR 5.46; p < 0.0001; and
HR 6.46; p < 0.0001), number of ≥4 CLM (HR 3.13; p = 0.0005; and HR 1.77; p = 0.0389), and carcinoembryonic
antigen (CEA) level of ≥100 ng/ml (HR 1.67; p = 0.032; and HR 1.67; p = 0.044). The presence of four criteria (PR, ≤3
CLM, ≤3 cm maximum size, and CEA ≤100 ng/ml) selected a subgroup (n = 23) with significantly higher
probabilities for OS and RFS at 5 years (39% and 22%,respectively) compared to those without any or up 3 of these
criteria (0-27% and 0-9%, p < 0.001, respectively).
Conclusions: A score based on four criteria (response to systemic therapy, ≤3 CLM, ≤3 cm size, low CEA value)
may allow to select patients with liver-only CLM for whom additional use of RFA most likely adds benefit in an
attempt to achieve long-term disease control. Almost one-fourth of patients fulfilling these four criteria may achieve
5-year survival without disease recurrence following effective systemic plus local RFA treatment.
Keywords: Colorectal cancer, Liver metastases, Radiofrequency ablation, Multimodality treatment, Prognostic
factors, Clinical scoreBackground
Hepatic resection is the only curative treatment for pa-
tients with colorectal liver metastases (CLM), with re-
ported 5-year survival rates ranging from 35 to more than
50% [1,2]. However, 80% of patients are not surgical candi-
dates because of advanced disease and/or comorbidities
and receive palliative systemic therapy. Despite the fact
that modern-agent regimens consisting of 5-fluorouracil,
leucovorin plus oxaliplatin (FOLFOX) or irinotecan (FOL-
FIRI) ± cetuximab and/or bevacizumab achieve response* Correspondence: a.stang@asklepios.com
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unless otherwise stated.rates up to 70% [3], complete pathological and/or durable
clinical response of CLM is rare [4,5], and patients will
typically relapse with decreasing efficacy with each
subsequent line of treatment [6,7]. Therefore, long-
term (5-year) overall survival (OS) and/or recurrence-
free survival (RFS) based on systemic therapy of CLM
alone is uncommon [8,9].
Radiofrequency ablation (RFA) has become a widely
used local therapy for unresectable CLM [10,11]. Several
cohort studies have reported 5-year OS rates of 15-48%
after RFA for liver-only CLM [12-18]. Although these re-
sults are influenced by selection bias, they consistently in-
dicate that 5-year OS is possible in numerous patients.
However, because all these studies report few, if any, datatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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known about their impact on clinical outcomes in the
RFA collective. Moreover, RFA is an additive, than an al-
ternative, to systemic therapy, which is the standard for
care. Despite this, to date, no widely accepted criteria exist
for the use of RFA for treatment of CLM in the context of
effective modern-agent therapies.
The recently published randomized phase II CLOCC
trial supports an impact on disease control by adding RFA
to chemotherapy for patients with liver-only CLM [19].
However, data on the long-term efficacy of this combined
approach are still limited, namely with respect to 5-year
RFS results. Moreover, the importance of response to sys-
temic treatment is still unclear, albeit response may impact
on the pattern of use and timing of RFA treatment. Also,
patient inclusion criteria in the CLOCC trial (up to 9
CLM of ≤4 cm in size) cover a prognostically heteroge-
neous group of patients and may not match the optimal
candidates for attaining complete local and long-term dis-
ease control by RFA treatment. These patients have to be
better identified, and their characteristics would be of
value for both clinical and research settings.
In the present study, we correlated clinical variables to
OS and RFS in 88 consecutive patients with >5 years of
follow-up after receiving RFA for liver-only CLM follow-
ing systemic therapy. Special emphasis was directed to the
importance of response to systemic therapy and the char-
acteristics of 5-year survivors without disease recurrence.
We attempted to develop a prognostic factor-based score
for predicting probabilities of OS and RFS in the pre-RFA
setting. The aim was to define selection criteria for pa-
tients with liver-limited CLM who may benefit from add-




We carried out a retrospective analysis of a prospect-
ively recorded database in a single institution with sys-
tematic review of patients with potential of at least
5 years of follow-up. The study was approved by the In-
stitutional Review Board “Clinical Ethics Committee” of
the Asklepios Hospital Altona. All patients provided
written informed consent for data collection and for sci-
entific evaluation of the data.
Patient cohort
Between January 2002 and December 2007, a total of 88
consecutive patients underwent RFA of CLM after
treatment with systemic therapy (combination chemo-
therapy ± bevacizumab or cetuximab) at the Asklepios
Hospital Altona. Inclusion criteria for RFA treatment were:
histologically confirmed colorectal adenocarcinoma, ≤5
unresectable liver-only CLM of ≤5 cm maximum size, andanticipated life expectancy of ≥6 months. Unresectability
was decided in a multidisciplinary staff meeting, including
hepatobiliary surgeons, radiologists, and oncologists. Rea-
sons for unresectability were: technical impossibility to
achieve R0 resection with preservation of ≥30% liver paren-
chyma (e.g. proximity of CLM to the portal vein and/or
CLM involving or abutting the vena cava, a major hepatic
vein branch, or 2 hepatic veins), contraindications to gen-
eral anaesthesia (deterioration of general condition and/or
cardiorespiratory disease), and patient refusal. Exclusion
criteria for RFA treatment were proximity of CLM to major
biliary structures and/or bleeding disorders.
Pre-RFA assessment
Pre-RFA treatment assessments included performance sta-
tus evaluation, liver function tests, carcinoembryonic anti-
gen (CEA) evaluation, and chest and abdomino-pelvic
computed tomography (CT) with contrast agent enhance-
ment at multiple phases (ie, early arterial phase, portal ven-
ous phase, and delayed venous phase). The time interval
between the last systemic therapy and RFA was 2–4 weeks.
Response to systemic therapy was determined according to
the Response Evaluation Criteria in Solid Tumors (RECIST)
and classified as partial response (PR), stable disease (SD),
and progressive disease (PD) [20].
RFA procedure
RFA was performed percutaneously under conscious sed-
ation (midazolam, 5–20 mg) and analgesia (fentanyl, 50–
250 μg) and guided by ultrasonography (US) or computed
tomography (CT). All ablations were performed using a
15-gauge needle with 10 expandable hook-shaped elec-
trode tines (LeVeen, Boston Scientific, Natick, MA, USA)
connected with a commercially available RF generator (RF
3000, Boston Scientific, Natick, MA, USA) capable of pro-
ducing 200 W of power. Based on the size of the targeted
CLM, the expandable needle electrode (3.0-4.0 cm of ex-
posed tip) was manually inserted into the target CLM.
Ablations were performed according to the protocols pro-
vided by the manufacturer. Primary end points for a tech-
nically successful ablation were ≥2 increases in tissue
impedance (roll-off) with an interablation delay of 30s.
For CLM with a diameter of ≤1,5 cm, one ablation was
performed using a single 3-cm exposed tip electrode. For
CLM of >1.5 cm in size, 2–4 overlapping ablations were
performed by using 3-4-cm exposed tip electrodes. Irre-
spective of the use of US or CT-guidance, US and
contrast-enhanced US (SonoVue, Bracco, Milan, Italy) was
performed routinely after electrode withdrawal, to assess
the volume of ablation achieved and to guide additional
ablations if the volume of the ablation was considered in-
sufficient in comparison with the pre-RFA tumor size
and/or margin. An RFA procedure was considered to be
complete when the ablated area encompassed the target
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mined by the transient hyperechoic zone (tumor cover-
age ≥1 cm) and by the lack of contrast enhancement
(tumor coverage ≥0.5 cm) at US at the end of the proced-
ure. Needle track ablation was performed to avoid possible
seeding of tumor cells and needle track hemorrhage.
Post-RFA assessment of treatment efficacy
Post-RFA assessments included contrast-enhanced chest
and abdomino-pelvic CT imaging and CEA evaluation.
Initial post-RFA CT imaging was performed 2–4 weeks
after RFA treatment to establish a new baseline, thereafter
every 3 months for the first 2 years, and thereafter every
6 months. Each follow-up study was compared to the CT
images before RFA and the new baseline CT studies after
RFA. Treatment efficacy was determined according to the
criteria proposed by the International Working Group on
Image-Guided Tumor Ablation [21]. In brief, primary
technical success was defined as absence of contrast
enhancement in the target CLM on post-RFA CT imaging
2–4 weeks after the RFA procedure. Secondary technical
success was defined as absence of contrast enhance-
ment after reablation. Complete ablation was defined
as an absence of contrast enhancement in the target
CLM ≥3 months after the RFA procedure. Local tumor
progression was defined as the development of new
focal areas of contrast enhancement at follow-up,
either within, or contiguous/adjacent to, the edge of RFA-
treated CLM that were previously considered to be com-
pletely ablated. All other new contrast-enhancing focal
lesions at other intra- and extrahepatic sites were consid-
ered new metastases and defined as intra- and/or extrahe-
patic recurrence.Post-RFA assessment of complications
Procedural complications were determined according to
the Society of Interventional Radiology (SIR) classification
system [22]. Major complications were defined as events as-
sociated with substantial morbidity and disability, increas-
ing the level of care and requiring surgical or radiological
interventions, blood transfusion, significant medical therap-
ies or longer hospital stay. All other complications were
considered minor.Data analysis
A chart review of patient demographics, clinical features,
tumour-related variables, treatment-related variables in-
cluding response to each applied systemic regimen, the
number of lines and treatment duration of systemic ther-
apy, survival, and the timing and pattern of recurrence
after RFA treatment were retrospectively analyzed for each
patient. All CT examinations before RFA treatment andfor follow-up studies were jointly reviewed by an on-staff
abdominal and interventional radiologist.
Statistical analysis
Categorical and continuous variables are expressed as
mean ± standard deviation, median (range), and fre-
quency. Actuarial OS and RFS probabilities were calcu-
lated by the Kaplan-Meyer method from the date of
first RFA treatment and compared using the log-rank
test. Factors subjected to univariate analysis were age,
gender, type of primary tumor (colon versus rectum),
nodal status of primary tumor (positive versus nega-
tive), synchronous CLM (versus metachronous), max-
imum CLM size, number of CLM, CEA level, and
response to systemic therapy. Factors found to be sig-
nificant on univariate analysis were subjected to multi-
variate analysis using a Cox proportional hazards
model. Estimation of RFS and OS was additionally ad-
justed for factors found to be present in the patients
achieving ≥5-year RFS after RFA treatment. For all
analyses, p values <0.05 were considered significant.
Statistical analyses were carried out using SAS Statis-
tical Software Version 9.1 (SAS, Institute Inc.; Cary,
North Carolina, USA).Results
Patient characteristics and chemotherapy details
Clinical features of the study cohort are summarized in
Table 1. The study population comprised 57 men and 31
women. Ages ranged from 36 to 85 years (mean, 67.8 years;
median, 69 years). At the time of RFA treatment, the me-
dian number of CLM was 2.5 (mean: 2.7; range 1–5), which
ranged from 0.8 to 5.0 cm in size (mean, 3.1 cm; median,
2.9 cm). With respect to the total exposure to antineoplas-
tic agents, patients received on average 3 lines of systemic
therapies before and after RFA treatment (mean, 3.1, range
1–5): a total of 57 patients had received 5-FU monotherapy
(65%), 81 (92%) FOLFOX, and 82 (93%) FOLFIRI; bevaci-
zumab and cetuximab had been given to 40 patients (45%)
and 16 patients (18%), respectively (Table 1).
Considering chemotherapy details before RFA treat-
ment, a total of 49 patients (56%) underwent RFA after
one line, 31 (36%) after two lines, and 9 (8%) after 3
lines of prior systemic therapy. The regimens of each
line are detailed in Table 2. Most frequently applied last
line regimens before RFA treatment were FOLFOX
(40% [35/88] and FOLFIRI (23% [20/88]). There was no
difference in tumor response prior to RFA for FOLFOX
and FOLFIRI (57% [20/35] vs. 50% [10/20], p >0.05). A
total of 49 patients underwent RFA during PR (56%), 13
patients (15%) had SD, and 26 patients (29%) had PD
after the immediate preceding systemic therapy prior to
RFA treatment (Tables 1 and 2).
Table 1 Baseline data for the study cohort
Characteristic Value
Patients (n = 88)
Male, n (%) 57 (65)
Female, n (%) 31 (35)
Mean age ± SD, years 67.8 ± 0.84
Primary tumor
Colon, n (%) 69 (78)
Rectum, n (%) 19 (22)
Node status
Positive, n (%) 65 (74)
Negative, n (%) 23 (26)
Colorectal liver metastases (CLM)
Synchronous, n (%) 22 (25)
Metachronous, n (%) 66 (75)
Mean number ± SD 2.7 ± 0.13
Number of 1–3 CLM, n (%) 67 (76)
Number of 4–5 CLM, n (%) 21 (24)
Mean maximum size ± SD, cm 3.1 ± 0.1
Maximum size≤ 3 cm, n (%) 51 (65)
Maximum size 3–5 cm, n (%) 27 (35)
CEA levels before RFA, ng/mL
Mean CEA level ± SD 132.2 ± 16.3
CEA≤ 100, n (%) 51 (58)
CEA > 100, n (%) 37 (42)
Main cause of unresectability
Expected liver remnant≤ 30%, n (%) 19 (22)
Proximity to critical structures, n (%) 22 (25)
Medical comorbidity, n (%) 37 (42)
Patient refusal, n (%) 10 (11)
Systemic therapies before RFA
Mean number of lines ± SD 1.5 ± 0.07
5-Fluorouracile, n (%) 36 (41)
5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), n (%) 59 (67)
5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI), n (%) 41 (47)
+ Bevacizumab, n (%) 13 (15)
+ Cetuximab, n (%) 5 (6)
Systemic therapies before and after RFA
Mean number of lines ± SD 3.1 ± 0.1
5-Fluorouracile, n (%) 57 (65)
5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), n (%) 81 (92)
5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI), n (%) 82 (93)
+ Bevacizumab, n (%) 40 (45)
+ Cetuximab, n (%) 16 (18)
Table 1 Baseline data for the study cohort (Continued)
Response to the immediate systemic therapy before RFA
Partial remission, n (%) 49 (56)
Stable disease, n (%) 13 (15)
Progressive disease, n (%) 26 (29)
Recurrence after RFA
Median time to recurrence, months (range) 8 (1–24)
Local tumor progression (RFA-site), n (%) 8 (9)
Intrahepatic recurrence, n (%) 33 (37)
Extrahepatic recurrence, n (%) 14 (16)
Intra-/and extrahepatic recurrence, n (%) 27 (31)
No recurrence, n (%) 6 (7)
Abbreviations: CEA, carcinoembryonic antigen; CLM, colorectal liver metastases;
RFA, radiofrequency ablation; SD, standard deviation.
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Primary technical success was achieved in 93.6% (221 of
236) CLM. Of the CLM, 6.4%% (15 of 236) required early
reablation due to residual enhancing tumor on follow-up
CT scans (≤2-4 weeks). Secondary technical success was
obtained in 100% (15 of 15). At a median follow-up of
99 months (range 63–134 months) following RFA
treatment, a total of 82 patients (93%) had developed
disease recurrence. The frequencies of first-site recur-
rences are shown in Table 1. Six patients (7%, [6/88])
remained recurrence-free >5-years following RFA treat-
ment (Table 3). There were no procedure-related
deaths. Adverse events related to the procedure were
observed in 10.2% of patients (9 of 88). Two patients
(2.3%) developed major complications (2× infected
biloma requiring drainage and antibiotic therapy). The
remaining 7 patients had one or more self-limiting
minor complications (5× fever, 2× pain, 2× pleural effu-
sions, and 1× small intrahepatic hematoma).Univariate and multivariate analysis
At univariate analysis, four factors significantly (p <
0.05, respectively) negatively influenced both OS and
RFS (Table 4): no response to the immediate pre-RFA
systemic therapy (Figures 1 and 2), lesion size >3 cm,
number of ≥4 CLM, and CEA level ≥100 ng/ml. At
multivariate analysis, independent negative prognos-
tic factors for OS and RFS were PD before RFA (haz-
ard ratio (HR) 5.46; p < 0.0001; and HR 6.46; p <
0.0001), ≥4 CLM HR 3.13; p = 0.0005; and HR 1.77;
p = 0.039), and CEA level ≥100 ng/ml (HR 1.67; p =
0.032; and HR 1.67; p = 0.044). It should be noted that
there were no patients achieving 5-year RFS with
CLM of >3 cm in size (Table 4).
Table 2 Details of systemic therapy before RFA treatment
Regimen Line of therapy and regimen administered Response to last line therapy regimen1
1st line 2nd line 3rd line Last line2 PR SD PD
5-FU, n 30 5 0 17 10 3 4
5-FU + Bevacizumab, n 1 0 0 1 1 0 0
FOLFOX, n (%) 31 19 2 35 (40) 20 5 10
FOLFOX + Bevacicumab, n 1 0 1 2 1 1 0
FOLFOX + Cetuximab, n 3 2 0 5 3 1 1
FOLFIRI, n (%) 18 12 1 20 (23) 10 1 9
FOLFIRI + Bevacizumab, n 3 4 3 8 3 3 2
FOLFIRI + Cetuximab, n 0 0 0 0 0 0 0
Total number (%) 88 (100) 40 (45) 8 (9) 88 (100) 49 13 26
Abbreviations: FOLFIRI, 5-fluorouracil,leucovorin, irinotecan; FOLFOX, 5-fluorouracil, leucovorin, oxaliplatin; RFA, radiofrequency ablation.
1RECIST-defined response to the last line regimen before RFA treatment. 249 patients (56%) received RFA after 1st line, 31 (36%) after 2nd line, and 8 (9%) after
3rd line therapy.
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To address the issue of patient selection, we developed
a prognostic scoring system for quantifying the prob-
abilities of OS and RFS of individual patients in the
pre-RFA setting. The scoring system was developed in
three steps. First, to determine criteria most strongly
associated with long-term disease control, we analyzed
the characteristics of the 6 patients obtaining 5-year
RFS. Uniformly, those patients presented with ≤3 CLM
of ≤3 cm maximum size after effective systemic ther-
apy (regardless of the regimen applied), and 5 of the 6 pa-
tients had CEA level ≤100 ng/ml (Table 3). Second, the
derivation of our prognostic scoring system started from
these four criteria and their reference categories (objective
response, ≤3 CLM, ≤3 cm, and CEA ≤100 ng/ml) because
of their strong association with long-term disease control
in our data set (Table 5). By assigning one point to each
criterion, we defined a scoring scale (score 0,1,2,3, or 4; in-
dicates the sum of the presence of zero, one, two, three, or
four criteria) and formed subgroups for scores 1,2, and 3Table 3 Characteristics of patients achieving ≥5-year survival
RFA for liver-only CLM
Patient Systemic therapy
Response1 No. of lines Regimen(s) administ
1 Partial remission 1 FOLFIRI
2 Partial remission 2 FOLFOX, FOLFIRI
3 Partial remission 1 FOLFOX
4 Partial remission 2 FOLFIRI + Bevacizumab, FOLFO
5 Partial remission 1 FOLFIRI + Bevacizum
6 Partial remission 1 FOLFOX
Abbreviations: CEA, carcinoembryonic antigen; CLM, colorectal liver metastases; FOLF
oxaliplatin; RFA, radiofrequency ablation.
1RECIST-defined response to the immediate preceding regimen before RFA treatme
before RFA treatment.(representing the combination of the presence or ab-
sence of criteria). Third, calculation of Kaplan-Meier
curves for OS and RFS adjusted on these scores and
subgroups created a scoring system providing estimates
for median and 5-year probabilities of OS and RFS
based upon the number and combination of the pres-
ence or absence of the four criteria (Table 6). The score
also separated two fundamental subsets (score 4 vs.
scores 0–3) with significantly different OS and RFS
curves across the entire cohort (p < 0.001). Patients
scoring 0–3 distributed along a wide range of median
times for OS (16–44 months) and RFS (4–11 months);
the 5-year probabilities for OS (0-27%) and RFS (0-9%)
were relatively low (Table 6). Patients scoring 4 (n = 23)
had significantly higher median times for OS (46 months
[95% CI 40–76 months]) and RFS (13 months [95%
CI 11–17 months]) and significantly higher 5-year prob-
abilities for OS (39% [95% CI 20-58%] and RFS (22%
[95% CI 8-40%]) compared to patients scoring 0–3 (p <
0.001, Figures 3 and 4, Table 6).without disease recurrence after systemic therapy plus
Clinical features
ered Number of CLM Size2 of CLM CEA level (ng/ml)
1 2.5 cm 12
1 2.1 cm 23
2 2.2 cm 13
X + Cetuximab 3 3.0 cm 114
ab 2 3.1 cm 57
1 2.7 cm 4
IRI, 5-fluorouracil, leucovorin, irinotecan; FOLFOX, 5-fluorouracil, leucovorin,
nt. 2after decrease of ≥30% in size following the immediate preceding regimen
Table 4 Univariate and multivariate analysis of variable factors for overall survival and recurrence-free survival
Overall survival Recurrence-free survival











p-value p-palue HR HR 95% CI
Age 0.8381 0.4263
≤ 60 years 16 19 (14–37) 8.3 (0.6-30.2) 8 (5–13) 13.3 (2.2-34.6)
> 60 years 72 25 (18–31) 12.4 (5.8-21.5) 8 (6–10) 5.6 (1.8-12.5)
Gender 0.6264 0.8117
Male 57 23 (17–30) 10.5 (3.9-28.4) 7 (5–11) 7.1 (2.3-15.8)
Female 31 24 (15–37) 14.3 (4.6-29.3) 9 (6–11) 6.5 (1.1-18.6)
Primary tumor 0.1872 0.7773
Colon 69 19 (16–27) 8.6 (3.3-17.2) 8 (6–10) 5.9 (1.9-13.2)
Rectum 19 33 (23–58) 23.7 (7.2-45.5) 7 (4–13) 10.5 (1.8-28.4)
Node status 0.8512 0.4566
Positive 65 25 (19–32) 11.4 (5.0-2.8) 8 (6–10) 6.2 (2.0-13.8)
Negative 23 18 (14–33) 13.0 (2.6-32.3) 10 (5–13) 9.1 (1.6-25.1)
CLM 0.9861 0.2889
Synchronous 22 20 (18–35) 9.1 (1.6-25.1) 10 (7–13) 4.5 (0.3-18.9)
Metachronous 66 26 (16–32) 12.4 (5.4-22.4) 7 (5–10) 7.7 (2.8-15.8)
CEA level before RFA 0.0189 0.0325 0.0062 0.0442
≤ 100 ng/ml 51 29 (19–37) 15.3 (6.7-27.0) 10 (8–12) 9.8 (3.6-19.7)
> 100 ng/ml 37 15 (11–25) 6.9 (1.4-19.1) 1.672 1.044-2.678 6 (4–7) 2.8 (0.2-12.4) 1.637 1.013-2.647
Maximum size of CLM 0.0001 0.0939 <0.0001 0.0771
≤ 3 cm 61 30 (23–36) 15.3 (7.2-26.1) 10 (8–11) 9.8 (4.0-18.8)
3-5 cm 27 12 (10–19) 3.8 (0.3-16.4) 1.548 0.928-2.581 5 (4–6) 0 1.600 0.950-2.694
Number of CLM <0.0001 <0.0001 0.0093 0.0389
1-3 67 27 (21–36) 15.6 (7.8; 25.9) 8 (7–11) 9.0 (3.6-17.2)
4-5 21 12 (10–18) 0 3.128 1.771-5.526 5 (4–10) 0 1.771 1.029-3.048
Response to systemic
therapy before RFA
<0.0001 0.0005 <0.0001 <0.0001
Partial remission 49 37 (32–48) 21.6 (10.9-34.7) 11 (10–13) 12.5 (5.1-23.4)
Stable disease 13 19 (15–25) 0 8 (6–10) 0
Progressive disease 26 10 (9–11) 0 5.456 2.289-13.005 4 () 0 6.458 2.644-15.78

















Figure 1 Kaplan-Meier plots of overall survival (OS). Stratification according to response to chemotherapy before radiofrequency ablation of
colorectal liver metastases. PR = partial remission; SD = stable disease; and PD = progressive disease.
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The clinical benefit from RFA as a treatment for CLM is
still being debated, and currently no criteria exist to select
patients for its use in the context of effective modern-
agent therapies. The results of this study indicate that mul-
timodality treatment of liver-limited CLM, consisting ofFigure 2 Kaplan-Meier plots of recurrence-free survival (RFS). Stratifica
ablation of colorectal liver metastases. PR = partial remission; SD = stable dieffective systemic therapy plus RFA, may offer the chance
to obtain long-term disease control for well-selected
patients. According to our findings, a scoring system
based on four criteria (response to systemic therapy, ≤3
CLM, ≤3 cm lesion size, and low CEA level) may facili-
tate selection of patients for RFA treatment for whomtion according to response to chemotherapy before radiofrequency
sease; and PD = progressive disease.
Table 5 Criteria used to build a prognostic score for
patient selection for RFA treatment of liver-only CLM in
the context of effective modern-agent systemic therapies
Variable Reference category Points
Systemic therapy Objective response1 1
Number of CLM ≤ 3 CLM 1
Maximum size of CLM ≤ 3 cm2 1
CEA level ≤ 100 ng/mL 1
Abbreviations: CEA, carcinoembryonic antigen; CLM, colorectal liver metastases;
RFA, radiofrequency ablation.
1RECIST-defined response to the immediate preceding systemic therapy
regimen before RFA treatment. 2after decrease of ≥30% in size following the
immediate preceding systemic therapy regimen before RFA treatment.
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fulfilling all four criteria (score 4) had significantly higher
probabilities for OS and RFS at 5 years after RFA treat-
ment (39% and 22%, respectively) compared to patients
scoring 0–3 (0-27% and 0-9%, respectively).
CEA level, number and size of CLM are well-known
prognostic factors in patients with RFA-treated CLM
[12-18], reflecting the tumor burden and limitations in
controlling CLM of ≥3 cm in size using RFA [10,11,23].
Specific to the present study, we found that response to
systemic therapy was the most powerful prognostic factor
in our RFA cohort, emphasizing the integration ofTable 6 Prognostic scoring system providing probabilities of su
four criteria for improving patient selection for RFA treatment
Clinical criteria
Score2 Subgroup3 Response4 PR No. of
CLM ≤ 3
Size of
CLM5 ≤ 3 cm
CEA value
100 ng/m
0 - - - -
1 1A - - - +
1B - - + -
1C - + - -
1D + - - -
2 2A - - + +
2B - + - +
2C + - - +
2D - + + -
2E + - + -
2 F + + - -
3 3A - + + +
3B + + - +
3C + - + +
3D + + + -
4 + + + +
Abbreviations: CEA, carcinoembryonic antigen; CLM, colorectal liver metastases; no, n
1outcome probabilities are based on adjusted Kaplan-Meyer calculations in this stud
represent combinations of present and absent criteria in patients scoring 1–3. 4REC
before RFA treatment. 5after decrease of ≥30% in size following the immediate preresponse into the decision making for RFA treatment. A
key feature of the prognostic score formulated in this
study is the combination of outcome indicators related to
both “tumor response” and “tumor burden”. This goes be-
yond establishing associations between single factors and
outcome and, instead, gives estimates of outcome for me-
dians and 5-year probabilities of OS and RFS that clini-
cians can use to guide their decision for RFA treatment of
CLM.
Our proposed scoring system is simple, based on four
widely available criteria, and usable in the context of ef-
fective modern-agent therapies. Although the relative im-
pact for recurrence and outcome varied somewhat for
these four criteria, we decided to assign each criterion one
point for simplicity and thus enhanced clinical applicabil-
ity. This design is supported by our data, which show that
the scoring system allows for a good prognostic discrimin-
ation and selection of patients for RFA treatment. Funda-
mentally, the total score assigning each criterion one
point defines two subgroups: patients who may (score
4) and patients who may not (scores 0–3) potentially ob-
tain 5-year RFS after RFA for CLM. Related to subgroups
for scores 1, 2, or 3, which represent the combination of
presence or absence of the criteria, patients distribute
along a wide range of different median OS and RFS times
(Table 6). This reflects the different relative prognosticrvival outcomes based on presence (+) or absence (−) of
of liver-only CLM in the era of effective systemic therapies1
Overall survival Recurrence-free survival
≤
L
median (months) 5-Years (%) median (months) 5-years (%)
16 0 4 0
17 0 3 0
19 0 6 0
19 0 4 0
31 0 11 0
18 0 4 0
24 0 5 0
no no no no
19 0 4 0
33 0 9 0
36 11 10 0
27 7 5 0
44 15 9 0
40 0 11 0
44 27 11 9
46 39 13 22
ot observed; PR, partial remission; RFA, radiofrequency ablation.
y cohort (n = 88). 2score indicates the sum of present criteria. 3subgroups
IST-defined response to the immediate preceding systemic therapy regimen
ceding systemic therapy regimen before RFA treatment.
Figure 3 Kaplan-Meier plots of overall survival (OS). Stratification according to the presence (score 4) versus partial or complete absence
(score 0–3) of 4 criteria before radiofrequency ablation of colorectal liver metastases. Criteria: (1) response to prior systemic therapy; (2) ≤3 CLM;
(3) ≤3 cm lesion size; and (4) carcinoembryonic antigen level ≤100 ng/mL.
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http://www.biomedcentral.com/1471-2407/14/500impact of the underlying criteria. Thus, the scoring system
may identify both patients potentially achieving long-term
disease control and patients achieving a clinically relevant
recurrence-free time without toxicity following RFA of
CLM.Figure 4 Kaplan-Meier plots of recurrence-free survival (RFS). Stratifica
absence (score 0–3) of 4 criteria before radiofrequency ablation of colorect
≤3 CLM; (3) ≤3 cm lesion size; and (4) carcinoembryonic antigen level ≤10The low use of targeted agents in our study reflects their
limited availability during the study period (2002–2007)
[3]. This excluded a meaningful analysis of new time-
related and/or non-size based modified RECIST criteria in
our response evaluation of systemic therapies prior totion according to the presence (score 4) versus partial or complete
al liver metastases. Criteria: (1) response to prior systemic therapy; (2)
0 ng/mL.
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can add prognostic information to conventional size-
based RECIST response categories used in this study when
assessing response to targeted agents such as cetuximab
[25] or bevacizumab [26]. Therefore, further refinement of
the RECIST methodology by modified RECIST criteria
would rather enhance than reduce the clinical usefulness
of our prognostic score, particularly with the new targeted
agents now available for routine use [7].
Almost one-fourth (22%) of our RFA-treated responders
to systemic therapy with a low residual tumor burden (≤3
CLM, ≤3 cm, low CEA value) achieved 5-year RFS. The
median RFS of 13 months is also clinically relevant and
underscores a beneficial effect from RFA within this sub-
group. Interestingly, our long-term results are consistent
with reported rates for 5-year RFS (9-32%) after RFA treat-
ment in particular subgroups with solitary and/or small
(≤3 cm) CLM [15,17] and/or CLM responding to chemo-
therapy [16].
For several reasons, a long-term result with a 5-year RFS
rate of 22% would probably be unrealizable in a similar
group of patients when treated with systemic therapy
alone. First, no study has yet reported the possibility of 5-
year RFS after systemic therapy of CLM alone. Second,
the best currently available evidence, the randomized
phase II CLOCC trial, supports a benefit with respect to
disease control by adding RFA to chemotherapy even for
patients with up to 9 CLM [19]. Thirdly, local response to
systemic therapy is rarely complete [4-6], and RFA can
improve local disease control. Because RFS captures the
time-related effect of both local and distant disease
control, it seems likely that RFA contributed to the 5-year
RFS observed.
For patients with liver-only CLM responding to sys-
temic therapy, reported 5-year rates of OS (≤15%,
[27,28]) are lower compared to that (39% [95% CI 20-
58%]) seen in a subset of our additionally RFA-treated
responders. It could be argued that patient selection
bias is responsible for this difference in OS. However,
one cannot absolutely exclude an impact on OS from
additional local therapy by RFA, as shown for patients
with CLM resected after response to chemotherapy
[2,27,28]. Although resection series and RFA series like
ours are hardly comparable, a similar finding is that re-
sponse to preoperative chemotherapy, number of ≤3
CLM, size of ≤3 cm, and low CEA level also represent
powerful predictors of postoperative outcome [1,28,29].
The long-term result, however, seen in our RFA series is
not as good as reported after resection of CLM responding
to chemotherapy, which results in rates for 5-year OS of
33-64% [1,2,28].
A limitation of this study is the retrospective nature of
observing treated patients including a methodically non-
avoidable selection bias. Our observations were alsolimited to a single-institutional experience. Additionally,
comparison with a group receiving chemotherapy alone
was not performed, because it was not possible to select a
population of patients receiving chemotherapy only with
comparable disease extent.
Conclusions
This study provides long-term outcome data indicating
the potential of 5-year survival without disease recur-
rence for a defined subgroup of patients receiving RFA
for liver-only CLM. The four criteria defining this sub-
group (response to systemic therapy, number of CLM, size
of CLM, and CEA level) may provide a clinical score for
predicting outcome and improving patient selection for
RFA treatment of CLM in the era of effective systemic
therapies. This score may also aid in the interpretation
and comparison of outcome data and conduct of clinical
trials, including defining a cohort that could be tested in a
randomized fashion. Further prospective multicenter stud-
ies are needed to confirm our findings, ideally designed as
randomized trials.
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